Mersana Strengthens Board of Directors Leadership with Appointment of Willard H. Dere, M.D., Professor at the University of Utah and Retired Chief Medical Officer of Amgen
March 19, 2018 08:00 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., March 19, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
Mersana Therapeutics to Present at Upcoming Investor Conferences
February 07, 2018 08:00 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 07, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., (NASDAQ:MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
Mersana Therapeutics Outlines 2017 Milestones and 2018 Goals
January 08, 2018 08:00 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., (NASDAQ:MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
Mersana Announces Third Quarter 2017 Financial Results and Provides Business Updates
November 09, 2017 16:01 ET
|
Mersana Therapeutics, Inc.
Received FDA Clearance of IND Application for XMT-1536, a First-in-Class Dolaflexin® Antibody Drug Conjugate Targeting NaPi2b XMT-1522 Phase 1 Trial Continues Enrollment of Patients with Advanced...
Mersana Announces FDA Clearance of IND Application for XMT-1536, a First-in-Class Antibody Drug Conjugate Targeting NaPi2b
October 30, 2017 07:30 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 30, 2017 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., (NASDAQ:MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
Mersana Therapeutics Presents New Data on XMT-1536, a NaPi2b Targeting Antibody Drug Conjugate, at the AACR-NCI-EORTC International Conference
October 30, 2017 07:00 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 30, 2017 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., (NASDAQ:MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
Mersana Therapeutics Announces Poster Presentation at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 23, 2017 16:01 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 23, 2017 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...